** Shares of drugmaker Vericel VCEL.O fall 12.7% to $51.25 in extended trading
** VCEL expects prelim Q4 revenue in the range of about $75.2 million to $75.7 million
** Analysts estimate Q4 revenue of $77.93 mln on average -data compiled by LSEG
** VCEL expects Q4 gross margin to be ~77% vs estimates of 75.43%
** Co expects 20% to 23% total revenue growth for 2025
** As of Dec 31, 2024, co had ~$167 million in cash, restricted cash and investments, and no debt - VCEL
** Up to last close, stock gained ~53% over the past 12 months
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.